$4.61 0.00 (%) Progenics Pharmaceuticals Inc - NASDAQ

Oct. 23, 2014 | 04:00 PM

Partner Headlines

  1. Progenics Receives $40M Milestone Following FDA Approval of RELISTOR For OIC Patients With Chronic Non-Cancer Pain

    Benzinga | Oct. 6, 2014 | 16:31PM EST
  2. Morning Market Losers

    Benzinga | Sep. 30, 2014 | 09:51AM EST
  3. US Stock Futures Signal Higher Start On Wall Street

    Benzinga | Aug. 11, 2014 | 07:44AM EST
  4. Earnings Scheduled For August 8, 2014

    Benzinga | Aug. 8, 2014 | 05:22AM EST
  5. Morning Market Movers

    Benzinga | Jul. 14, 2014 | 09:38AM EST
  6. Benzinga's Top #PreMarket Gainers

    Benzinga | Jul. 14, 2014 | 08:10AM EST
  7. US Stock Futures Surge; All Eyes On Citigroup Results

    Benzinga | Jul. 14, 2014 | 07:29AM EST
  8. UPDATE: Salix, Progenics Report FDA Office Of Drug Evaluation III Approves Salix Request For FDA Approval Of RELISTOR sNDA

    Benzinga | Jul. 14, 2014 | 07:06AM EST
  9. Progenics Announces Will Host Call Related to FDA Appeal Response Related to RELISTOR sNDA

    Benzinga | Jul. 14, 2014 | 07:06AM EST
  10. Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday

    Benzinga | Jun. 12, 2014 | 09:41AM EST
  11. Small Pharmaceuticals Rallying Following FDA Report

    Benzinga | Jun. 9, 2014 | 12:49PM EST
  12. Mid-Afternoon Market Update; Hertz Down, QuikSilver Gain On CEO & CFO Share Purchases

    Benzinga | Jun. 6, 2014 | 15:01PM EST
  13. Mid-Day Market Update: Diamond Foods Shares Fall After Weak Earnings; GW Pharma Gains

    Benzinga | Jun. 6, 2014 | 12:37PM EST
  14. Earnings Scheduled For May 9, 2014

    Benzinga | May. 9, 2014 | 05:18AM EST
  15. Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

    Benzinga | Apr. 24, 2014 | 10:17AM EST
  16. US Stock Futures Edge Higher Ahead Of McDonald's Earnings

    Benzinga | Apr. 22, 2014 | 07:31AM EST
  17. Salix Pharmaceuticals, Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand Use of RELISTORby the European Medicines Agency

    Benzinga | Apr. 22, 2014 | 07:02AM EST
  18. Earnings Scheduled For March 13, 2014

    Benzinga | Mar. 13, 2014 | 04:51AM EST
  19. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts | Feb. 12, 2014 | 09:31AM EST
  20. Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors

    Benzinga | Jan. 29, 2014 | 16:49PM EST
  21. Progenics Pharmaceuticals Relaunches Registrational Trial of Azedra to Treat Pheochromocytomas

    Benzinga | Nov. 25, 2013 | 05:59AM EST
  22. Earnings Scheduled For November 11, 2013

    Benzinga | Nov. 11, 2013 | 04:46AM EST
  23. Salix Pharmaceuticals Thrives With Promising GI Drugs

    IBD | Nov. 4, 2013 | 13:00PM EST
  24. Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX

    GuruFocus | Jan. 27, 2013 | 08:09AM EST
  25. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,215 Shares

    GuruFocus | Jan. 23, 2013 | 04:35AM EST
  26. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,142 Shares

    GuruFocus | Dec. 26, 2012 | 07:36AM EST
  27. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,607 Shares

    GuruFocus | Nov. 30, 2012 | 06:35AM EST
  28. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 11,800 Shares

    GuruFocus | Nov. 20, 2012 | 08:06AM EST
  29. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 49,793 Shares

    GuruFocus | Nov. 19, 2012 | 08:05AM EST
  30. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 48,833 Shares

    GuruFocus | Nov. 16, 2012 | 08:05AM EST
  31. Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 10:06AM EST
  32. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,162 Shares

    GuruFocus | Oct. 25, 2012 | 08:02AM EST
  33. Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX

    GuruFocus | Oct. 1, 2012 | 06:50AM EST
  34. Progenics Pharmaceuticals Inc. (PGNX) CEO Mark Robert Baker buys 1,036 Shares

    GuruFocus | Sep. 27, 2012 | 13:00PM EST
  35. 5 Stocks That Dropped the Most Since Gurus Bought Them

    GuruFocus | Sep. 13, 2012 | 11:23AM EST
  36. EZchip Semiconductor, Sagent Pharmaceuticals Among Stocks setting 52-Week Lows Friday

    FoxBusiness | Aug. 10, 2012 | 06:33AM EST
  37. Salix trounces Q2 estimates

    IBD | Aug. 9, 2012 | 13:00PM EST
  38. Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 9, 2012 | 10:22AM EST
  39. Salix Pharmaceuticals Beats, Announces Licensing Deal

    IBD | Aug. 9, 2012 | 06:20AM EST
  40. ProShares Trust Ultra VIX Short Term Futures ETF, Direxion Daily Large Cap Bear 3X Shares Among Stocks hitting 52-Week Lows Friday

    FoxBusiness | Aug. 3, 2012 | 06:33AM EST
  41. Stocks Finish Little Changed Ahead of Central Bank Meetings with Coca-cola (KO) and Chicago Bridge & Iron (CBI) on the Move

    MarketIntelligenceCenter | Jul. 30, 2012 | 16:29PM EST
  42. Salix, Progenics Stocks Fall On Drug Approval Delay

    IBD | Jul. 30, 2012 | 04:40AM EST
  43. Stock Futures Mixed; Salix, Progenics Tumble

    IBD | Jul. 30, 2012 | 03:17AM EST
  44. Benzinga's Top Pre-Market Losers

    Benzinga | Jul. 30, 2012 | 02:22AM EST
  45. Financial Breakfast: Morning News Summary for July 30, 2012

    Benzinga | Jul. 30, 2012 | 01:29AM EST
  46. Salix Q1 Results Beat Estimates; Raises EPS Guidance

    IBD | May. 7, 2012 | 12:21PM EST
  47. Microcap Movers for Tuesday December 20, 2011

    Benzinga | Dec. 20, 2011 | 14:33PM EST
  48. Stocks Bounce Back In Big Volume

    IBD | Dec. 20, 2011 | 09:57AM EST
  49. Progenics Pharma Up 30% on Positive Phase 3 Results

    Benzinga | Dec. 20, 2011 | 08:42AM EST
  50. Notable Call Options Activity in Progenics Pharmaceuticals

    Benzinga | Dec. 20, 2011 | 03:41AM EST
Trading Center